Please login to the form below

fitusiran

This page shows the latest fitusiran news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Meanwhile, another non-clotting factor drug for haemophilia – Alnylam and Sanofi’s RNA interference candidate fitusiran – is also in late-stage development for haemophilia A and B.

Latest news

Sanofi narrows focus, shedding diabetes and cardiovascular research

This includes a host of investigational therapies for rare disease and cancers, such as Fitusiran (an RNAi therapeutic for haemophilia A and B), BIVV001 (a factor VIII therapy for haemophilia A)
Roche’s Hemlibra scores broader NHS funding

Competition is heating up in haemophilia, however. Alnylam's late-stage candidate fitusiran is tipped as a major competitor to Hemlibra, while the first gene therapies are also on the horizon.
ACPs to lead gene therapies in haemophilia market growth

New therapies to hit existing players. Roche’s Hemlibra and Alnylam’s late-stage candidate fitusiran are likely to seize a bigger share of an expanded haemophilia market than gene therapies, ... The two drugs have distinct mechanisms – Hemlibra
Sanofi exits R&D pact with Alnylam on rare disease

The R&D deal was tweaked in January last year, with Sanofi licensing an RNAi drug called fitusiran for haemophilia A and B as well as other rare bleeding disorders, but ... Prospects for haemophilia candidate fitusiran looked a little shaky in 2017 when
FDA lifts clinical hold on Sanofi’s haemophilia drug

Fitusiran holds the potential to help improve the lives of people living with haemophilia,” said Akin Akinc, who is leading the development of the drug at Alnylam. ... With the additional risk mitigation measures in place, we look forward to the

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma leaders to watch in 2020

pipeline. The company submitted its lumasiran candidate for primary hyperoxaluria to the FDA and has another ATTR amyloidosis candidate – called vutrisiran – in late-stage along with Sanofi-partnered fitusiran for haemophilia
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

instead taking a lead marketing role for their co- developed haemophilia candidate fitusiran. ... Alnylam has three more RNAi medicines in its late stage pipeline: Fitusiran in haemophilia, being co-developed with Sanofi; inclisiran for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Medical Editor: Competitive

Account Director – Creative Healthcare Communications: Competative

Healthcare Lead Copywriter: Competitive

Healthcare Senior Account Manager: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Commercial Finance Director, Healthcare Marketing Communications...: up to £90K

Healthcare Account Director: Competitive

PMHub

Add my company

Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Patient recruitment and retention 2021 state of play: At COUCH Health, we’ve recently done some social listening to look into the discussions around ‘patient recruitment’ and ‘patient retention’, to see if these conversations have been impacted by the...
The UK has approved the first vaccine for COVID-19. What now?: The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
Clinical trials and the diversity principle: If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....